PCA
NVS icon

Providence Capital Advisors’s Novartis NVS Stock Holding History

Providence Capital Advisors’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Sell
32,898
-79
-0.2% -$11.8K 0.78% 50
2026
Q1 		$5.04M Buy
32,977
+895
+3% +$137K 0.82% 52
2025
Q4 		$4.42M Buy
32,082
+1,108
+4% +$145K 0.74% 53
2025
Q3 		$3.97M Buy
30,974
+845
+3% +$103K 0.69% 55
2025
Q2 		$3.65M Buy
30,129
+840
+3% +$94.7K 0.67% 58
2025
Q1 		$3.27M Buy
29,289
+369
+1% +$39.3K 0.68% 60
2024
Q4 		$2.81M Buy
28,920
+7
+0% +$746 0.57% 69
2024
Q3 		$3.33M Sell
28,913
-6,620
-19% -$751K 0.66% 64
2024
Q2 		$3.78M Buy
35,533
+416
+1% +$41.8K 0.82% 50
2024
Q1 		$3.4M Buy
35,117
+813
+2% +$83.4K 0.74% 57
2023
Q4 		$3.46M Sell
34,304
-1,103
-3% -$106K 0.83% 52
2023
Q3 		$3.61M Buy
35,407
+193
+0.5% +$19.6K 0.94% 51
2023
Q2 		$3.55M Buy
35,214
+518
+1% +$51.8K 0.9% 52
2023
Q1 		$3.19M Buy
34,696
+588
+2% +$51.4K 0.84% 53
2022
Q4 		$3.09M Sell
34,108
-2
-0% -$168 0.84% 55
2022
Q3 		$2.59M Buy
34,110
+698
+2% +$57.9K 0.78% 59
2022
Q2 		$2.82M Buy
33,412
+10,595
+46% +$930K 0.82% 57
2022
Q1 		$1.99M Buy
22,817
+1,835
+9% +$159K 0.49% 82
2021
Q4 		$1.83M Buy
20,982
+833
+4% +$69.2K 0.51% 74
2021
Q3 		$1.65M Buy
20,149
+1,857
+10% +$167K 0.51% 74
2021
Q2 		$1.67M Buy
18,292
+1,095
+6% +$97.5K 0.54% 68
2021
Q1 		$1.47M Buy
17,197
+372
+2% +$33.4K 0.53% 69
2020
Q4 		$1.59M Buy
16,825
+1,715
+11% +$150K 0.65% 57
2020
Q3 		$1.31M Buy
15,110
+488
+3% +$42.3K 0.69% 54
2020
Q2 		$1.28M Sell
14,622
-122
-0.8% -$10.5K 0.72% 53
2020
Q1 		$1.22M Buy
+14,744
New +$1.32M 0.73% 56
2018
Q1 		– Sell
-50
Closed -$4K – 285
2017
Q4 		$4K Buy
+50
New +$3.77K ﹤0.01% 279

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Providence Capital Advisors's NVS Position: Q2 2026 in Review

Providence Capital Advisors reduced its Novartis (NVS) stake by 0.24% in Q2 2026, selling an estimated $11.8K and leaving 32,898 shares worth $5.16M. The position accounts for 0.78% of the portfolio, ranked #50.

Providence Capital Advisors first reported a position in NVS in Q4 2017 and has held it in 27 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Providence Capital Advisors held 32,898 shares of Novartis worth $5.16M as of Q2 2026.
  • Providence Capital Advisors sold 79 Novartis shares in Q2 2026, an estimated $11.8K.
  • Novartis made up 0.78% of Providence Capital Advisors's portfolio in Q2 2026, its #50 holding.
  • Providence Capital Advisors first reported a position in Novartis in Q4 2017 and has held it in 27 quarters since.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.